Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: Evidence of utility beyond a single indication

Archives of Dermatology

Volumn 144, Issue 5, 2008, Pages 683-685

  Williams, Bronwyn ^b   Vanags, Daina ^b   Hall, Stephen ^b   McCormack, Chris ^b   Foley, Peter ^b   Weiss, Julissa ^b   Johnson, Barbara ^b   Latz, Eicke ^b   Feeney, Dennis ^a  

^a CBio Limited   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONIN; XTOLL;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SCOTOMA; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; CHAPERONIN 10; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 44249087380     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.5.683     Document Type: Letter

References (4)

1. Johnson BJ, Le TT, Dobbin CA, et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem. 2005; 280(6):4037-4047.
2. Vanags D, Williams B, Johnson B, et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet. 2006;368(9538):855-863.
3. Murphy JE, Robert C, Kupper TS. Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J Invest Dermatol. 2000;114(3):602-608.
4. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139(6):719-727.